To the Moon
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice to see new traders catching on!
Looks like the fun has just begun! HZHI with the POWER hour rally .35x .50 +133% on over 50k shares traded. Look how low that float is. Boooooms on air!
Agreed a second rejection would be a shot to the foot. I have faith they will pull it off this time around. $CHMJF Long and strong!
$AXNVF $AXF.V moving up on news Axion Reports Press Tour for Invictus with Apple and Announces Inagural Esports Tournament in Thailand https://www.otcmarkets.com/stock/AXNVF/news/Axion-Reports-Press-Tour-for-Invictus-with-Apple-and-Announces-Inagural-Esports-Tournament-in-Thailand?id=231160
CHMJF News from yesterday!
Chemistree Partner, ACS, to File New Jersey Application Under New DOH Mandate
VANCOUVER, June 10, 2019
VANCOUVER, June 10, 2019 /PRNewswire/ - Chemistree Technology Inc. (CSE: CHM) (US OTCQB: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that its partner Applied Cannabis Sciences of New Jersey ("ACS"), is readying an Application under the new Request for Applications (RFA) program announced by the Department of Health on June 3, 2019. In total, the Department will seek up to 24 cultivation endorsements, up to 30 manufacturing endorsements, and up to 54 dispensary endorsements. As allowable, ACS will be applying for all three permit types, creating a vertically integrated model for the business.
New Jersey's State Legislature also passed a medical marijuana program expansion bill (Senate Nos. 10 and 2426) last week that is separate from the RFA announcement. It is anticipated that New Jersey Governor Phil Murphy will sign the bill into law once the aforementioned RFA is underway. This legislation will create another new opportunity to apply for licensure in late 2019 as well, significantly expanding the base of medical cannabis operations in the state as it gears up for a voter referendum on Adult Use legislation in 2020. Gov. Murphy has been outspoken in his support for recreational cannabis use in the state since his election campaign in 2016.
Chemistree partnered with ACS in April 2019 to assist ACS with their qualification process as a potential applicant, and to provide Chemistree with a toehold into the cannabis industry on the eastern seaboard of the United States. This new call for applications marks a significant acceleration by the state of New Jersey to their expansion timelines and ACS is well-prepared to file once the applications become available on July 1, 2019. ACS placed in the top-20 during last summer's RFA out of 147 applicants, where only six licenses were made available. As such, CHM plans to make an early investment into ACS, acquiring 10 percent of the entity, with an option for a larger stake upon licensure.
This rapid and unprecedented expansion of the medical marijuana program in New Jersey is geared toward increasing the patient count to over 200,000 people, as well as setting up the Adult Use industry in New Jersey.
Chemistree board member Nico Escondido, a New Jersey resident and founding member of the ACS team commented, "New Jersey has a goal to be a national – and, in fact, global – leader in medical cannabis research and development, which is why our partnerships with Rutgers Medical School, Stockton University, and RWJ Barnabas Healthcare is critical to our work. Our goal is to position New Jersey as the epicenter of this work on the east coast."
Karl Kottmeier, Chemistree's President stated "When we entered discussions to participate with ACS, we were particularly impressed by the team of industry experts they had assembled, and their deep local knowledge of the dynamic, developing New Jersey market for medical cannabis. The fact that the state authorities have recognized the need to expand the total number of licenses and speed-up their licensing process is certain to be welcome news to a large and under-served population and a huge opportunity for ACS."
New Jersey is home to over nine million people currently being served by only six existing cannabis operators. Six additional participants were selected in 2018 but have not yet commenced operations. A legal, Adult Use (21+) industry in New Jersey would effectively open up the tri-state area to one of the largest cannabis markets in the country, with the total population of NY, PA and NJ totalling over 40 million people.
About Chemistree Technology Inc.
Chemistree Technology Inc. is an investment company dedicated to the U.S. cannabis sector, endeavoring to provide turn-key solutions for the regulated cannabis industry. The Company's corporate strategy is to acquire and develop vertically integrated cannabis assets, leveraging management's decades of expertise in the cannabis industry and corporate finance to own and operate licensed cultivation, processing, distribution and retail facilities. Outside of Washington State, Chemistree owns the exclusive worldwide rights to the Sugarleaf brand. For more information, visit www.Chemistree.ca.
Advisory
The Company wishes to inform shareholders that there are significant legal restrictions and regulations that govern the cannabis industry in both Canada and the United States.
Cannabis-related Practices or Activities are Illegal Under U.S. Federal Laws
The concepts of "medical cannabis" and "recreational cannabis" do not exist under U.S. federal law. The Federal Controlled Substances Act classifies "marihuana" as a Schedule I drug. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision. As such, cannabis related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. Strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under U.S. federal law, nor will it provide a defence to any federal proceeding which may be brought against the Company. Enforcement of U.S. federal laws will be a significant risk to the business of the Company and any such proceedings brought against the Company may adversely affect the Company's operations and financial performance.
Further information regarding the legal status of cannabis related activities and associated risk factors, including, but not limited to, risk of enforcement actions, risks that third-party service providers, such as banking or financial institutions cease providing services to the Company, and the risk that Company may not be able to distribute profits, if any, from U.S. operations up to the Company, are included in the Prospectus, the Company's annual information form and other documents incorporated by reference therein and in the Company's Form 2A listing statement filed with the CSE and available under the Company's profile on SEDAR at www.sedar.com.
"Karl Kottmeier"
President
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Information set forth in this news release includes forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", "budget", "scheduled" and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation, statements relating to: the timing, completion and construction of greenhouses and other facilities; potential production quantities; and the receipt of all California state and local licenses for the growing, processing, manufacture and distribution of cannabis products.
By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others: establishing a trading market for the Debenture and Warrants; fluctuations in the market price of the Common Shares, Debentures and Warrants; risks relating to the dilution of the Common Shares, Debentures and Warrants; risks and uncertainties relating to the actual use of the net proceeds of the Offering; changes in market conditions; an exchange on which the Company's shares are listed may initiate a delisting review; stock price volatility; sales by shareholders of a substantial number of Common Shares, Debentures or Warrants; the failure to sign agreements with a strategic partner in respect of the Company's facilities in Washington State; the failure to obtain required regulatory approvals in respect of the DHS Property; the failure to complete the Company's proposed loan to a Humboldt County-based cannabis processing company located in Arcata, California; and the risks identified in the Company's reports and filings with the applicable Canadian securities regulators, including, without limitation, all risks in and incorporated by reference into the Company's preliminary short-form prospects in respect of the Offering.
Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made, and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.
Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/chemistree-partner-acs-to-file-new-jersey-application-under-new-doh-mandate-300864426.html
SOURCE Chemistree Technology Inc.
CHMJF News from yesterday!
Chemistree Partner, ACS, to File New Jersey Application Under New DOH Mandate
VANCOUVER, June 10, 2019
VANCOUVER, June 10, 2019 /PRNewswire/ - Chemistree Technology Inc. (CSE: CHM) (US OTCQB: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that its partner Applied Cannabis Sciences of New Jersey ("ACS"), is readying an Application under the new Request for Applications (RFA) program announced by the Department of Health on June 3, 2019. In total, the Department will seek up to 24 cultivation endorsements, up to 30 manufacturing endorsements, and up to 54 dispensary endorsements. As allowable, ACS will be applying for all three permit types, creating a vertically integrated model for the business.
New Jersey's State Legislature also passed a medical marijuana program expansion bill (Senate Nos. 10 and 2426) last week that is separate from the RFA announcement. It is anticipated that New Jersey Governor Phil Murphy will sign the bill into law once the aforementioned RFA is underway. This legislation will create another new opportunity to apply for licensure in late 2019 as well, significantly expanding the base of medical cannabis operations in the state as it gears up for a voter referendum on Adult Use legislation in 2020. Gov. Murphy has been outspoken in his support for recreational cannabis use in the state since his election campaign in 2016.
Chemistree partnered with ACS in April 2019 to assist ACS with their qualification process as a potential applicant, and to provide Chemistree with a toehold into the cannabis industry on the eastern seaboard of the United States. This new call for applications marks a significant acceleration by the state of New Jersey to their expansion timelines and ACS is well-prepared to file once the applications become available on July 1, 2019. ACS placed in the top-20 during last summer's RFA out of 147 applicants, where only six licenses were made available. As such, CHM plans to make an early investment into ACS, acquiring 10 percent of the entity, with an option for a larger stake upon licensure.
This rapid and unprecedented expansion of the medical marijuana program in New Jersey is geared toward increasing the patient count to over 200,000 people, as well as setting up the Adult Use industry in New Jersey.
Chemistree board member Nico Escondido, a New Jersey resident and founding member of the ACS team commented, "New Jersey has a goal to be a national – and, in fact, global – leader in medical cannabis research and development, which is why our partnerships with Rutgers Medical School, Stockton University, and RWJ Barnabas Healthcare is critical to our work. Our goal is to position New Jersey as the epicenter of this work on the east coast."
Karl Kottmeier, Chemistree's President stated "When we entered discussions to participate with ACS, we were particularly impressed by the team of industry experts they had assembled, and their deep local knowledge of the dynamic, developing New Jersey market for medical cannabis. The fact that the state authorities have recognized the need to expand the total number of licenses and speed-up their licensing process is certain to be welcome news to a large and under-served population and a huge opportunity for ACS."
New Jersey is home to over nine million people currently being served by only six existing cannabis operators. Six additional participants were selected in 2018 but have not yet commenced operations. A legal, Adult Use (21+) industry in New Jersey would effectively open up the tri-state area to one of the largest cannabis markets in the country, with the total population of NY, PA and NJ totalling over 40 million people.
About Chemistree Technology Inc.
Chemistree Technology Inc. is an investment company dedicated to the U.S. cannabis sector, endeavoring to provide turn-key solutions for the regulated cannabis industry. The Company's corporate strategy is to acquire and develop vertically integrated cannabis assets, leveraging management's decades of expertise in the cannabis industry and corporate finance to own and operate licensed cultivation, processing, distribution and retail facilities. Outside of Washington State, Chemistree owns the exclusive worldwide rights to the Sugarleaf brand. For more information, visit www.Chemistree.ca.
Advisory
The Company wishes to inform shareholders that there are significant legal restrictions and regulations that govern the cannabis industry in both Canada and the United States.
Cannabis-related Practices or Activities are Illegal Under U.S. Federal Laws
The concepts of "medical cannabis" and "recreational cannabis" do not exist under U.S. federal law. The Federal Controlled Substances Act classifies "marihuana" as a Schedule I drug. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision. As such, cannabis related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. Strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under U.S. federal law, nor will it provide a defence to any federal proceeding which may be brought against the Company. Enforcement of U.S. federal laws will be a significant risk to the business of the Company and any such proceedings brought against the Company may adversely affect the Company's operations and financial performance.
Further information regarding the legal status of cannabis related activities and associated risk factors, including, but not limited to, risk of enforcement actions, risks that third-party service providers, such as banking or financial institutions cease providing services to the Company, and the risk that Company may not be able to distribute profits, if any, from U.S. operations up to the Company, are included in the Prospectus, the Company's annual information form and other documents incorporated by reference therein and in the Company's Form 2A listing statement filed with the CSE and available under the Company's profile on SEDAR at www.sedar.com.
"Karl Kottmeier"
President
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Information set forth in this news release includes forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", "budget", "scheduled" and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation, statements relating to: the timing, completion and construction of greenhouses and other facilities; potential production quantities; and the receipt of all California state and local licenses for the growing, processing, manufacture and distribution of cannabis products.
By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others: establishing a trading market for the Debenture and Warrants; fluctuations in the market price of the Common Shares, Debentures and Warrants; risks relating to the dilution of the Common Shares, Debentures and Warrants; risks and uncertainties relating to the actual use of the net proceeds of the Offering; changes in market conditions; an exchange on which the Company's shares are listed may initiate a delisting review; stock price volatility; sales by shareholders of a substantial number of Common Shares, Debentures or Warrants; the failure to sign agreements with a strategic partner in respect of the Company's facilities in Washington State; the failure to obtain required regulatory approvals in respect of the DHS Property; the failure to complete the Company's proposed loan to a Humboldt County-based cannabis processing company located in Arcata, California; and the risks identified in the Company's reports and filings with the applicable Canadian securities regulators, including, without limitation, all risks in and incorporated by reference into the Company's preliminary short-form prospects in respect of the Offering.
Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made, and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.
Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/chemistree-partner-acs-to-file-new-jersey-application-under-new-doh-mandate-300864426.html
SOURCE Chemistree Technology Inc.
Chemistree Partner, ACS, to File New Jersey Application Under New DOH Mandate
Chemistree Partner, ACS, to File New Jersey Application Under New DOH Mandate
VANCOUVER, June 10, 2019
VANCOUVER, June 10, 2019 /PRNewswire/ - Chemistree Technology Inc. (CSE: CHM) (US OTCQB: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that its partner Applied Cannabis Sciences of New Jersey ("ACS"), is readying an Application under the new Request for Applications (RFA) program announced by the Department of Health on June 3, 2019. In total, the Department will seek up to 24 cultivation endorsements, up to 30 manufacturing endorsements, and up to 54 dispensary endorsements. As allowable, ACS will be applying for all three permit types, creating a vertically integrated model for the business.
New Jersey's State Legislature also passed a medical marijuana program expansion bill (Senate Nos. 10 and 2426) last week that is separate from the RFA announcement. It is anticipated that New Jersey Governor Phil Murphy will sign the bill into law once the aforementioned RFA is underway. This legislation will create another new opportunity to apply for licensure in late 2019 as well, significantly expanding the base of medical cannabis operations in the state as it gears up for a voter referendum on Adult Use legislation in 2020. Gov. Murphy has been outspoken in his support for recreational cannabis use in the state since his election campaign in 2016.
Chemistree partnered with ACS in April 2019 to assist ACS with their qualification process as a potential applicant, and to provide Chemistree with a toehold into the cannabis industry on the eastern seaboard of the United States. This new call for applications marks a significant acceleration by the state of New Jersey to their expansion timelines and ACS is well-prepared to file once the applications become available on July 1, 2019. ACS placed in the top-20 during last summer's RFA out of 147 applicants, where only six licenses were made available. As such, CHM plans to make an early investment into ACS, acquiring 10 percent of the entity, with an option for a larger stake upon licensure.
This rapid and unprecedented expansion of the medical marijuana program in New Jersey is geared toward increasing the patient count to over 200,000 people, as well as setting up the Adult Use industry in New Jersey.
Chemistree board member Nico Escondido, a New Jersey resident and founding member of the ACS team commented, "New Jersey has a goal to be a national – and, in fact, global – leader in medical cannabis research and development, which is why our partnerships with Rutgers Medical School, Stockton University, and RWJ Barnabas Healthcare is critical to our work. Our goal is to position New Jersey as the epicenter of this work on the east coast."
Karl Kottmeier, Chemistree's President stated "When we entered discussions to participate with ACS, we were particularly impressed by the team of industry experts they had assembled, and their deep local knowledge of the dynamic, developing New Jersey market for medical cannabis. The fact that the state authorities have recognized the need to expand the total number of licenses and speed-up their licensing process is certain to be welcome news to a large and under-served population and a huge opportunity for ACS."
New Jersey is home to over nine million people currently being served by only six existing cannabis operators. Six additional participants were selected in 2018 but have not yet commenced operations. A legal, Adult Use (21+) industry in New Jersey would effectively open up the tri-state area to one of the largest cannabis markets in the country, with the total population of NY, PA and NJ totalling over 40 million people.
About Chemistree Technology Inc.
Chemistree Technology Inc. is an investment company dedicated to the U.S. cannabis sector, endeavoring to provide turn-key solutions for the regulated cannabis industry. The Company's corporate strategy is to acquire and develop vertically integrated cannabis assets, leveraging management's decades of expertise in the cannabis industry and corporate finance to own and operate licensed cultivation, processing, distribution and retail facilities. Outside of Washington State, Chemistree owns the exclusive worldwide rights to the Sugarleaf brand. For more information, visit www.Chemistree.ca.
Advisory
The Company wishes to inform shareholders that there are significant legal restrictions and regulations that govern the cannabis industry in both Canada and the United States.
Cannabis-related Practices or Activities are Illegal Under U.S. Federal Laws
The concepts of "medical cannabis" and "recreational cannabis" do not exist under U.S. federal law. The Federal Controlled Substances Act classifies "marihuana" as a Schedule I drug. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision. As such, cannabis related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. Strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under U.S. federal law, nor will it provide a defence to any federal proceeding which may be brought against the Company. Enforcement of U.S. federal laws will be a significant risk to the business of the Company and any such proceedings brought against the Company may adversely affect the Company's operations and financial performance.
Further information regarding the legal status of cannabis related activities and associated risk factors, including, but not limited to, risk of enforcement actions, risks that third-party service providers, such as banking or financial institutions cease providing services to the Company, and the risk that Company may not be able to distribute profits, if any, from U.S. operations up to the Company, are included in the Prospectus, the Company's annual information form and other documents incorporated by reference therein and in the Company's Form 2A listing statement filed with the CSE and available under the Company's profile on SEDAR at www.sedar.com.
"Karl Kottmeier"
President
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Information set forth in this news release includes forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", "budget", "scheduled" and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation, statements relating to: the timing, completion and construction of greenhouses and other facilities; potential production quantities; and the receipt of all California state and local licenses for the growing, processing, manufacture and distribution of cannabis products.
By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others: establishing a trading market for the Debenture and Warrants; fluctuations in the market price of the Common Shares, Debentures and Warrants; risks relating to the dilution of the Common Shares, Debentures and Warrants; risks and uncertainties relating to the actual use of the net proceeds of the Offering; changes in market conditions; an exchange on which the Company's shares are listed may initiate a delisting review; stock price volatility; sales by shareholders of a substantial number of Common Shares, Debentures or Warrants; the failure to sign agreements with a strategic partner in respect of the Company's facilities in Washington State; the failure to obtain required regulatory approvals in respect of the DHS Property; the failure to complete the Company's proposed loan to a Humboldt County-based cannabis processing company located in Arcata, California; and the risks identified in the Company's reports and filings with the applicable Canadian securities regulators, including, without limitation, all risks in and incorporated by reference into the Company's preliminary short-form prospects in respect of the Offering.
Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made, and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.
Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/chemistree-partner-acs-to-file-new-jersey-application-under-new-doh-mandate-300864426.html
SOURCE Chemistree Technology Inc.
$CHMJF $CHM.V http://schrts.co/MdWfGQCf Chart is oversold and ready to come off a bottom! Keep it on your watchlist for a bounce opportunity!
$CHMJF $CHM.V http://schrts.co/MdWfGQCf Chart is oversold and ready to come off a bottom! Keep it on your watchlist for a bounce opportunity!
$CHMJF $CHM.V http://schrts.co/MdWfGQCf Chart is oversold and ready to come off a bottom! Keep it on your watchlist for a bounce opportunity!
Amplitech Publishes Investor Q&A
https://www.otcmarkets.com/stock/AMPG/news/Amplitech-Publishes-Investor-QA?id=230059
Bohemia, NY, May 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AmpliTech Group, Inc. (OTCQB: AMPG): Amplitech (AMPG) filed its Form 10-Q on May 14, 2019, and received some follow up questions from investors regarding its strategy. In the interest of keeping the market fully informed, we have published the questions and answers below:
Question 1:
Investor:
Have you received any patents on your low noise amplifier (LNA) designs? If not, when do you expect to receive them?
Fawad Maqbool, CEO:
We rely on our “trade secrets” as opposed to patents with our current product range in order to preserve the technical know-how, as we believe that published patents would allow our competitors to more easily understand what makes our LNAs perform better than the competition. However, we plan to pursue patents for the new technology that we are developing in the rapidly growing 4G/5G wireless base station and satellite communications markets. This new technology will be more suitable for obtaining patents, which would then be prudent.
Question 2:
Investor:
Do you offer integrated circuit (IC) based amplifiers now? If not, when do you expect to offer them in the pipeline?
Fawad Maqbool, CEO:
We currently do not offer IC based amplifiers, but our medium term goal is to incorporate our unique proprietary technology into ICs to attempt to provide a superior solution to our competitors in the market, and to eventually make our technology accessible to OEMs for large volume applications such as PDAs, servers, routers, and IoT products. Our near-term focus is to develop the best amplifiers in the wireless base station and airline Wi-Fi connectivity arena where we currently have an active market with significant growth opportunities.
Question 3:
Investor:
For the new acquisition of Specialty Microwave Corporation (SMW), do you expect any cannibalization or are the products complementary?
Fawad Maqbool, CEO:
There is no duplication or cannibalization. The two product lines are complementary and expand our product offering into larger systems with higher average selling prices (ASP) and value-added products to new and existing customers. In fact, our amplifier products will be designed into SMW’s existing products to hopefully increase the volume and margin of our products/business.
Question 4:
Investor:
Just curious about growth strategy and targets and discussion on possible endgame.
Fawad Maqbool, CEO:
Given the current relatively small market capitalization and limited resources of our company as compared to some of our listed peers such as Qorvo (QRVO) and Skyworks (SWKS), we have adapted a prudent approach to growth, which consists of building upon our existing IP/assets/competitive advantages to grow organically in the markets for which we and SMW have a natural advantage, while also selectively looking for opportunities to acquire breakthrough IP and/or like-minded competitors. SMW was the first step in this direction, but I am also very excited by the products and technology that we have in-house that we hope to exploit in the coming months and years, as we gain momentum and attract capital on the best possible terms. We have a medium term plan to grow through product innovation, by building our sales team, through acquisition of IP where it makes sense and through the acquisition of like-minded competitors where it makes sense.
Amplitech and SMW will have Booth #1250 at the International Microwave Symposium (IMS) in Boston from June 2-7th, where we look forward to discussing our products with the multitude of customers that attend this global show. Anyone interested in meeting with us at the show can send us an email with a requested meet date at info@amplitechinc.com.
For more information on IMS, see the link below:
https://ims-ieee.org/
About AmpliTech Group, Inc.
AmpliTech Group, Inc. designs, develops, and manufactures custom and standard state-of-the-art RF components for the Domestic and International, SATCOM, Space, Defense and Military markets. These designs cover the frequency range from 50 kHz to 40 GHz - eventually, offering designs up to 100 GHz. AmpliTech also provides consulting services to help with any microwave components or systems design problems. Our steady growth over the past 13+ years has come about because we can provide complex, custom solutions for nearly ANY custom requirements that are presented us. In addition, we have the best assemblers, wires, and technicians in the industry and can provide contract assembly of customers' own designs. Click here to view AmpliTech video. Website: http://www.AmpliTechinc.com
Forward-looking Statements
This release contains statements that constitute forward-looking statements. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.
Twitter: https://twitter.com/AmpliTechAMPG
Instagram: https://www.instagram.com/amplitechampg/
Facebook: https://www.facebook.com/AmpliTechInc
Fawad Maqbool
631-521-7831
fmaqbool@amplitechinc.com
I completely agree, slow steady ascent is more sustainable too. $AMPG holding its gains nicely and is set to keep grinding higher!
LLNKF up 26% was up over 50% earlier at the highs of .30 I expect it to return to those highs soon! Its trading in a nice uptrend, higher highs and higher lows!
If your having issues buying #LLNKF through other online brokers I suggest using Etrade. No problems routing orders to buy from them. Sometimes Schwab and other discount firms make you call orders in on penny stocks, never had that issue through Etrade!
$LLNKF .195 +56% on over 540k shares traded, closed near the high of day (.197) Be on the lookout for more solid gains!
LLNKF Video chart
That is a key statistic to point out, great catch. The fact that they are paying down their bills, have cash in hand and are growing the business with increasing sales and revenues is outstanding. $AMPG is doing all of the right things!
It can only go up from here, $AMPG is significantly undervalued!
Some excellent numbers. looking forward to seeing significant increases in sales and revenues from $AMPG
Amplitech also announced its intention to acquire the assets of SMW last week. The acquisition of SMW’s assets by Amplitech is expected to result in increased sales ($4.5-5.0 million), an increased order book ($2.1-2.5 million) and increased EBITDA ($800-900 thousand) on an annualized proforma basis, upon completion of the acquisition, which is expected by the end of July 2019. The acquisition will be funded with cash on hand and through the issue of 5 year, 6 percent interest only, promissory notes issued to the owner of SMW. As such, the acquisition is not expected to result in any issue of new Amplitech shares and should result in improved earnings per share for existing Amplitech shareholders.
Amplitech Announces First Quarter Results for 2019Press Release | 05/14/2019
Link to today's PR
Bohemia, NY, May 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AmpliTech Group, Inc. (OTCQB: AMPG): Amplitech’s momentum continued in the first quarter of 2019, reporting strong sales, improved profits, increased cash on hand, an expanded Board and an agreement to buy Specialty Microwave Corporation (SMW), a complementary business to Amplitech with complementary products and common customers.
Sales in the first quarter were $678.3 thousand, up from $428.5 thousand a year earlier, an improvement of $249.8 thousand, or 58.3 percent.
Gross profits in the first quarter were $324.1 thousand, up from $254.9 thousand a year earlier, an improvement of $69.2 thousand, or 27.1 percent. Gross margins in the first quarter were 47.8 percent, down from 59.5 percent the prior year. Gross margins were lower in 2019 vs 2018 due to a large order placed by a customer that was outsourced at a lower margin. In the longer term, Amplitech is seeking to have an optimal mix of higher volume, lower margin, outsourced business with higher margin, lower volume, more complex/higher performance components/systems, resulting in the highest possible throughput at the highest possible operating margins. In addition, outsourced production frees up the Amplitech facility to produce higher margin, lower volume, engineered solutions for its customers’ needs, which can be transitioned to an outsourced model if/when the customer moves to increased volumes in that particular line.
Operating Income in the first quarter increased to $82.6 thousand, up from $44.2 thousand a year earlier, an improvement of $38.4 thousand, or 86.9 percent. Earnings before interest, tax, depreciation and amortization (EBITDA) for the first quarter increased to $119.7 thousand from $52.1 thousand the prior year, an increase of $67.6 thousand, or 129.8 percent. EBITDA margins for the current quarter were 17.6 percent vs 12.2 percent in 2018, an improvement of 44.3 percent. The improved EBITDA and EBITDA margins were driven by increased throughput and a more optimal use of in-house and outsourced production.
Cash on hand increased from $442.1 thousand in the first quarter of 2018 to $783.6 thousand in 2019, helped by improved profits as well as a new term debt facility which was secured in the first quarter.
Amplitech also announced its intention to acquire the assets of SMW last week. The acquisition of SMW’s assets by Amplitech is expected to result in increased sales ($4.5-5.0 million), an increased order book ($2.1-2.5 million) and increased EBITDA ($800-900 thousand) on an annualized proforma basis, upon completion of the acquisition, which is expected by the end of July 2019. The acquisition will be funded with cash on hand and through the issue of 5 year, 6 percent interest only, promissory notes issued to the owner of SMW. As such, the acquisition is not expected to result in any issue of new Amplitech shares and should result in improved earnings per share for existing Amplitech shareholders.
In commenting on the most recent quarter, Fawad Maqbool, Founder and CEO of Amplitech, said: “This past quarter was a breakthrough quarter for our company. We grew our business organically, significantly improved our balance sheet, expanded our Board, agreed on our first acquisition and improved relations with capital providers, and, importantly, kicked off a concerted strategy of growing both organically and through acquisitions in a responsible, measured approach while ensuring that we minimize any dilution to our shareholders in the medium term.”
About AmpliTech Group, Inc.
AmpliTech Group, Inc. designs, develops, and manufactures custom and standard state-of-the-art RF components for the Domestic and International, SATCOM, Space, Defense and Military markets. These designs cover the frequency range from 50 kHz to 40 GHz - eventually, offering designs up to 100 GHz. AmpliTech also provides consulting services to help with any microwave components or systems design problems. Our steady growth over the past 13+ years has come about because we can provide complex, custom solutions for nearly ANY custom requirements that are presented us. In addition, we have the best assemblers, wires, and technicians in the industry and can provide contract assembly of customers' own designs. Click here to view AmpliTech video. Website: http://www.AmpliTechinc.com
Forward-looking Statements
This release contains statements that constitute forward-looking statements. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.
Twitter: https://twitter.com/AmpliTechAMPG
Instagram: https://www.instagram.com/amplitechampg/
Facebook: https://www.facebook.com/AmpliTechInc
Fawad Maqbool, CEO and Chairman
fawad@amplitechinc.com
$CHMJF In a consolidation holding higher lows gearing up for another move north soon http://schrts.co/TRHqwQFA
I would have to agree, they made a smart bet! SMW being less then 3miles away will make for a very smooth seamless transition. Everything is lining up for $AMPG the sun, moon and stars. Time to go intergalactic!
Thanks, for sure $AMPG chart is very pretty! https://stockcharts.com/h-sc/ui?s=ampg
Even after Friday’s move past .06, AMPG‘s market cap is only just above the $3M mark, although we would argue that even at that price, the stock is still grossly undervalued at present. Especially when one considers that it’s notably less than the combined expected annual sales of AMPG and the pending acquisition target, which you can read about in the 8-K filed this morning.
Don't sleep on $AMPG, they announced a BIG acquisition on Friday that essentially doubles their revenues. Go read up on it and look at that impressive client list! https://www.otcmarkets.com/stock/AMPG/news/AmpliTech-Enters-into-Agreement-to-Acquire-Specialty-Microwave-Creates-Significant-Synergies-in-Core-Business?id=227887
Don't sleep on $AMPG, they announced a BIG acquisition on Friday that essentially doubles their revenues. Go read up on it and look at that impressive client list! https://www.otcmarkets.com/stock/AMPG/news/AmpliTech-Enters-into-Agreement-to-Acquire-Specialty-Microwave-Creates-Significant-Synergies-in-Core-Business?id=227887
I can read through the B.S. when all of a sudden it(large sellers) vanished after a few buys hit. Then again, this is what I do all day every day the market is open! (Read Level 2's, chart patterns and breakdown DD etc.)
$AMPG L2 Shifted once a few buys came in. Did you notice how the size reduced as soon as a couple buys hit the ask? Looks like the sellers were showing fake offers to try and accumulate more shares on the bid in my opinion. Its a scare tactic that often happens in the OTC. The longs in $AMPG are too savvy to fall for that old trick. Today's news is a great example of why its a good idea to be a longer term investor in $AMPG. They are growing revenues with this strategic acquisition. Once the market digests the significance of this news I expect to see the PPS much higher!
Oh yeah that should make for a seamless transition! Go $AMPG
$AMPG News getting picked up by other newsletter sites
Today's acquisition news was structured nicely without any Dilution. I don't think Fawad is going to be doing anything different going forward especially if he hasn't thus far. Management at $AMPG knows how to structure deals properly and now with Mr. Homschek on board they are taking extra steps to secure proper non toxic financing to accommodate future acquisitions in a proper manner.
This mornings $AMPG PR is Outstanding News... "AMPG expects that the acquisition should result in a doubling of AMPG’s 2018 revenue of $2.4 million on a run rate basis within 2-3 months of closing the acquisition, which is expected to occur at the completion of an audit of SMW’s assets by AMPG’s auditors, as required by the SEC."
https://www.otcmarkets.com/stock/AMPG/news/Amplitech-Enters-Into-Agreement-to-Acquire-Specialty-Microwave-Creates-Significant-Synergies-in-Core-Business?id=227824
Accumulation is underway
Chemistree Technology Inc OTCMKTS: CHMJF Acquires Ownership Stake in The Physician’s Choice CBD LLC
Chemistree Technology Inc OTCMKTS: CHMJF Acquires Ownership Stake in The Physician’s Choice CBD LLC
Chemistree Technology Inc OTCMKTS: CHMJF Acquires Ownership Stake in The Physician’s Choice CBD LLC
Chemistree Technology Inc OTCMKTS: CHMJF Acquires Ownership Stake in The Physician’s Choice CBD LLC